Get access
Advertisement

Construction and Evaluation of Hemoglobin-Based Capsules as Blood Substitutes

Authors

  • Yi Jia,

    1. Beijing National Laboratory for Molecular Sciences, CAS Key Lab of Colloid and Interface Science, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
    Search for more papers by this author
  • Yue Cui,

    1. Beijing National Laboratory for Molecular Sciences, CAS Key Lab of Colloid and Interface Science, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
    Search for more papers by this author
  • Jinbo Fei,

    1. Beijing National Laboratory for Molecular Sciences, CAS Key Lab of Colloid and Interface Science, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
    Search for more papers by this author
  • Mingchun Du,

    1. Beijing National Laboratory for Molecular Sciences, CAS Key Lab of Colloid and Interface Science, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
    Search for more papers by this author
  • Luru Dai,

    1. National Center for Nanoscience and Technology, Beijing 100190, China
    Search for more papers by this author
  • Junbai Li,

    Corresponding author
    1. Beijing National Laboratory for Molecular Sciences, CAS Key Lab of Colloid and Interface Science, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
    2. National Center for Nanoscience and Technology, Beijing 100190, China
    • Beijing National Laboratory for Molecular Sciences, CAS Key Lab of Colloid and Interface Science, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
    Search for more papers by this author
  • Yang Yang

    Corresponding author
    1. National Center for Nanoscience and Technology, Beijing 100190, China
    • National Center for Nanoscience and Technology, Beijing 100190, China.
    Search for more papers by this author

Abstract

Hemoglobin-based capsules for use as blood substitutes are successfully fabricated by covalent layer-by-layer assembly. Dialdehyde heparin (DHP) is used both as one of the wall components and a cross-linker without employing other extraneous or toxic crosslinking agents. The biocompatibility of (Hb/DHP)6 microcapsules is evaluated through the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay and cell experiments. The hemocompatibility of (Hb/DHP)6 microcapsules is characterized in terms of prothrombin time, thrombin time, activated partial thromboplastin time, and hemolysis rate. The oxygen-carrying capacity of the microcapsules is demonstrated by converting the deoxy-Hb state of the microcapsules into the oxy-Hb state. All these results demonstrate that the hemoglobin-based microcapsules exhibit oxygen-carrying capacity as well as biocompatibility and hemocompatility, indicating that the as-prepared capsules have great potential to function as blood substitutes.

Get access to the full text of this article

Ancillary